Investment Strategy
& Management

Sunstone Life Science Ventures invests in early-stage life science companies developing novel therapeutics for humans. Our geographical scope is Europe including UK with particular emphasis on the European life science hubs. 

Our point of entry differs depending on the type of opportunity; however, we usually invest when drug candidates are a year from first-in-man or in clinical phase I. 

Sunstone Life Science Ventures’ investment strategy has a strong industry focus, and we believe that most exits in the life science sector will continue to take place in the M&A space. To appear on the radar of potential acquirers, we invest in opportunities that truly stand out in terms of both science and market positioning. We seek opportunities which target real unmet medical needs for patients, and we seek products which, once approved, have a clear path towards attractive reimbursement and pricing structures. 

We believe that the single most important factor when developing a successful company is the quality of the management team. This does not mean that we only invest in serial entrepreneurs with a strong track record. But less experienced management teams should be open to change if needed to accelerate the company. 

We are committed to working hands-on with our portfolio companies to build value. In order to do so, Sunstone is represented on the board of directors and works closely with the management team and the other board members to develop the company. 

As a unique offering, aimed at building the value of our portfolio companies, we offer access to Sunstone’s Business Development Advisory Board, established in 2007 and consisting of leading Life Science senior executives who have all been involved hands-on in licensing, partnerships and M&A’s on the buy-side.